Your Revenue Cycle Vendor Is Standing on a Melting Ice Block

Let me put something in plain terms.

A large part of the administrative services layer that sits underneath healthcare today is operating on an economic model that has already begun to break, even if it doesn’t look that way yet from the outside.

On paper, things still seem steady. Contracts haven’t meaningfully shifted. Service delivery continues. Invoices look familiar. But beneath that surface, the cost structure that supported those agreements has changed in a fundamental way, and when the math changes inside a private-equity-backed services business, behavior tends to follow.

Between 2018 and 2023, most scaled revenue cycle and administrative services firms were acquired at high multiples, often in the range of 15x to 20x EBITDA. A vendor generating $100 million in revenue at a 25% margin, roughly $25 million in EBITDA, could easily command an enterprise value of $375 million to $500 million, with leverage layered on top at five to seven times EBITDA.

That structure assumed stability: stable labor economics, stable pricing, stable delivery.

What was actually acquired

But what was actually acquired was not a technology-native execution system. It was a labor-driven model coordinated by software.

The real work in prior authorization, coding, utilization review and care management has always been performed by trained humans reading documentation, applying rule sets, making determinations and routing outcomes. Technology improved efficiency but did not remove the dependency. Pricing reflected that reality because labor formed the cost floor.

The cost floor is shifting

Agentic AI does not simply accelerate human work. In many workflows, it allows the deterministic portion of the volume, often 70% to 85%, to be handled autonomously. Historically, humans reviewed nearly every case not because each required judgment, but because legacy infrastructure could not reliably distinguish straightforward scenarios from complex ones.

New systems can make that distinction.

Which means that a majority of the work that previously required full human intervention can now be handled at a dramatically different cost base. Instead of a $50,000 to $75,000 annual human input per functional unit, equivalent execution may sit closer to a few thousand dollars in system cost.

This is not a marginal efficiency gain. It is a structural shift in production economics.

And yet, most contracts still reflect the earlier model.

Vendors are not inclined to volunteer that gap. Their valuations and capital structures were built on the assumption of stable revenue supported by labor-based delivery. If customers begin pricing against AI-native delivery, revenue can compress rapidly while fixed operating layers, infrastructure, compliance, leadership, remain comparatively sticky.

Consider a representative vendor that once generated $100 million in revenue with $25 million in EBITDA while carrying $125 million in debt. If repricing gradually reduces revenue to $25 million while margins compress toward 10%, EBITDA may fall to $2.5 to $3 million.

Against annual interest obligations of roughly $8 to $9 million, that creates a very different financial posture.

Why this creates continuity risk

This does not produce sudden failure. It produces drift.

Investment slows. Talent retention becomes harder. Operational decisions begin to favor preservation over advancement. Service quality rarely collapses overnight, but resilience can weaken gradually while everything still appears intact.

This is where continuity risk begins to build.

What it means for providers and payers

Meanwhile, on the provider side, a health system with $2 billion in net patient revenue may be spending somewhere between $40 million and $80 million annually across outsourced administrative workflows.

If the AI-native cost of delivering comparable workflows now sits at 30% to 40% of that spend, the margin differential becomes material. Over time, that may translate into $25 million to $50 million annually that could remain inside the organization rather than supporting a vendor’s capital structure.

For payers managing several billion dollars in medical spend, even modest administrative efficiency improvements can influence medical loss ratio in ways that directly affect competitiveness.

The timing matters

Today, many vendors continue negotiating within the assumptions of the past even as delivery economics evolve underneath them. That creates a temporary window where repricing conversations can occur from relative stability rather than under distress.

Once repricing becomes widespread, conversations tend to shift from adjustment to transition, and transitions introduce their own operational complexities.

What I am suggesting is not a procurement exercise or a vendor replacement process.

It is simply taking a structured look at your administrative supply chain, where exposure exists, where leverage may sit, and whether current agreements still reflect operational reality.

Perhaps they do. If so, that clarity is valuable.

If they do not, understanding where change is possible allows action to be deliberate rather than reactive.

If this feels like a worthwhile discussion, I would be glad to spend time reviewing it together.

‍